Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Zatloukal

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Lung Cancer (Amsterdam, Netherlands)|February 27, 1999
Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II studyP Zatloukal, E Kanitz, P Magyar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2010
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)M Reck, J von Pawel, P Zatloukal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patientsJ Jassem, R Ramlau, H Karnicka-Młodkowska, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 20, 2008
A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancerM H Cullen, P Zatloukal, S Sörenson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2009
Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancerE H Tan, J Rolski, T Grodzki, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|November 11, 2010
[TARCEVA Clinical Registry]J Skricková, M Pesek, P Zatloukal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 1, 1996
Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative groupC Manegold, P Drings, A Pawinski, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|October 30, 2012
[The TULUNG clinical registry]S Spelda, J Skřičková, Z Bortlíček, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2011
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancerC Manegold, N van Zandwijk, A Szczesna, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Lung Cancer (Amsterdam, Netherlands)|February 27, 1999
Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II studyP Zatloukal, E Kanitz, P Magyar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2010
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)M Reck, J von Pawel, P Zatloukal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 5, 2002
A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patientsJ Jassem, R Ramlau, H Karnicka-Młodkowska, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 20, 2008
A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancerM H Cullen, P Zatloukal, S Sörenson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2009
Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancerE H Tan, J Rolski, T Grodzki, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|November 11, 2010
[TARCEVA Clinical Registry]J Skricková, M Pesek, P Zatloukal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 1, 1996
Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative groupC Manegold, P Drings, A Pawinski, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|October 30, 2012
[The TULUNG clinical registry]S Spelda, J Skřičková, Z Bortlíček, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2011
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancerC Manegold, N van Zandwijk, A Szczesna, et al.
Pageof 5